Tamara Klein is an associate in the firm’s Business Law Department and a member of its Private Equity Group. She joined Goodwin in 2015.

Prior to joining Goodwin, Ms. Klein was an associate in the Boston office of Locke Lord LLP.

Ms. Klein is a member of the American Bar Association and Boston Bar Association.

Areas of Practice




Ms. Klein’s work for clients has included representing and/or advising:

  • Ampersand Capital Partners in its acquisition of a majority stake in Corpus Medical, a provider of consulting and manufacturing services for development and commercialization of interventional medical devices. 
  • Florida Biologix in its merger with Brammer Biopharmaceuticals LLC, forming Brammer Bio, LLC, a cell and gene therapy biologics contract development and manufacturing organization.
  • Avista Pharma in its acquisition of the GMP contract manufacturing, development and animal health services business of Scynexis, Inc. (NASDAQ: SCYX).*
  • Nitinol Devices and Components, Inc. (“NDC”) in its acquisition of Interface Catheter Solutions (“Interface”). NDC is the largest contract manufacturer of nitinol-based medical devices and Interface is a pioneer is medical balloon technology and the leading contract manufacturer of balloon catheter systems. Following the acquisition, NDC and Interface created Confluent Medical Technologies, a leading contract manufacturer of specialized medical devices.*
  • Ampersand Capital Partners in its acquisition of Protein Technologies, a maker of peptide synthesizers and reagents.*
  • Accuratus Lab Services, an Ampersand Capital Partners portfolio company, in its acquisition of certain assets related to the chemistry, manufacturing and control testing services business of Array BioPharma Inc.*
  • Represented NutraMed, an Ampersand Capital Partners portfolio company, in its acquisition of Nutritional Laboratories International, Inc.*
  • Nautic Partners in its acquisition of Custom Windows, a leading designer and manufacturer of impact resistant and non-impact windows.*
  • GnuBio Inc., a developer of fully integrated droplet-based DNA sequencing technology, as general counsel and in its acquisition by Bio-Rad Laboratories, Inc.*

*Denotes experience prior to joining Goodwin.





J.D., 2013
Suffolk University Law School

(cum laude)

B.S., 2005
Connecticut College

(cum laude)



Get In Touch
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.


Search Other Lawyers